Nabi Biopharmaceuticals Announces Third Quarter 2007 Financial Results and Positive Vote from November 8, 2007 Special Stockholde...(able 6042 ...),Health

Inventories (313) (2,513)

Prepaid expenses and other current assets (188) (184)

Other assets 28 146

Accounts payable and accrued expenses 3,242 (4,053)

Total adjustments 15,279 13,513

Net cash used in operating activities from

continuing operations (16,614) (31,927)

Net cash used in operating activities from

discontinued operations (6,187) (6,023)

Net cash used in operating activities (22,801) (37,950)

Cash flow from investing activities:

Purchases of marketable securities (29,475) (68,075)

Proceeds from sales of marketable

securities 40,250 40,322

Proceeds from sale of assets, net of

closing costs 1,300 8

Capital expenditures (784) (2,145)

Net cash provided by (used in) investing

activities from continuing operations 11,291 (29,890)

Net cash provided by investing activities

from discontinued operations 2,582 -

Net cash provided by (used in) investing

activities 13,873 (29,890)

Cash flow from financing activities:

Repayments of capital leases (224) (116)

Proceeds from exercise of employee

stock options 673 1,238

Net cash provided by financing activities

from continuing operations 449 1,122

Net cash p
'/>"/>